Updated: Dec 8, 2024
Onchilles Pharma unveiled findings at AACR 2024 from the late-stage preclinical data of its two candidates: N17350 and N17465 (read the release here).
PharmaShots had an engaging dialogue exchange with Lev Becker, Associate Professor, University of Chicago and Cofounder, Onchilles Pharma
Lev highlights the unique novel mechanism that Onchilles Pharma leverages to treat a wide range of cancers
To read the article, click here.